Merck Signs US$922.5 M Collaboration with OPKO Health for Epstein-Barr Virus Vaccine
By Lalit Mishra & Lucy Haggerty
Pharma Deals Review: Vol 2023 Issue 3 (Table of Contents)
Published: 17 Mar-2023
DOI: 10.3833/pdr.v2023.i3.2771 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Jumping into the cancer vaccine arena, Merck has signed a global licensing agreement with Opko Health’s subsidiary, ModeX Therapeutics, for a vaccine candidate MDX-2201 targeting the Epstein-Barr virus (EBV) which could be worth up to US$922...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS